This prospective, randomized, double-blind, placebo-controlled, multicenter study treated patients with 30 ml cerebrolysin daily for 21 days, beginning 24 to 72 hours after stroke onset, alongside standardized rehabilitation
Once frozen and thawed, the solution appears normal but has lost therapeutic activity and must be discarded
6.1 Ferroptosis as a therapeutic target in neurodegeneration With growing interest in ferroptosis across various degenerative diseases and organ injuries, numerous inhibitors have been identified that effectively slow disease progression under different pathological conditions, with several advancing to preclinical or clinical investigation
BPC-157 is a 15-amino-acid synthetic peptide derived from a cytoprotective fraction of human gastric juice
With its unrivaled healing properties, BPC 157 has emerged as a game-changer in supporting the body's natural healing processes